US20130272922A1 - Antimicrobial composition and methods for using same - Google Patents
Antimicrobial composition and methods for using same Download PDFInfo
- Publication number
- US20130272922A1 US20130272922A1 US13/847,876 US201313847876A US2013272922A1 US 20130272922 A1 US20130272922 A1 US 20130272922A1 US 201313847876 A US201313847876 A US 201313847876A US 2013272922 A1 US2013272922 A1 US 2013272922A1
- Authority
- US
- United States
- Prior art keywords
- composition
- bacteria
- osm
- acid
- biofilm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
- A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
- A01N41/04—Sulfonic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/02—Amines; Quaternary ammonium compounds
- A01N33/12—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/36—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
Definitions
- Bacteria is found virtually everywhere and is responsible for a significant amount of disease and infection. Ridding surfaces of bacteria is desirable to reduce human exposure. Bacteria in normal environments have developed self preservation mechanisms and are therefore extremely difficult to remove and/or eradicate.
- Bacteria can be found in both planktonic and biofilm forms. In the biofilm form, they interact with surfaces and form surface colonies which adhere to a surface and continue to grow.
- the bacteria produce exopolysaccharide (EPS) and/or extracellularpoly-saccharide (ECPS) macromolecules that keep them attached to the surface and form a protective film that is effective against many forms of attack. Protection most likely can be attributed to the small diameter of the flow channels in the matrix, which restricts the size of molecules that can transport to the underlying bacteria, and consumption of biocides through interactions with portions of the EPS/ECPS macromolecular matrix.
- EPS exopolysaccharide
- ECPS extracellularpoly-saccharide
- the bacteria in biofilm form are down-regulated (sessile) and not actively dividing. This makes them resistant to attack by a large group of antibiotics and antimicrobials, which attack the bacteria during the active parts of their lifecycle, e.g., cell division.
- biocides and antimicrobials that are effective in treating bacteria in this form are strongly acidic, oxidizing, and toxic, often involving halogen atoms, oxygen atoms, or both.
- Common examples include concentrated bleach, strong mineral acids (e.g., HCl) and hydrogen peroxide.
- concentrated bleach strong mineral acids (e.g., HCl) and hydrogen peroxide.
- large dosages of such chemicals are allowed to contact the biofilm for extended amounts of time (up to 24 hours in some circumstances), which makes them impractical for many applications.
- Such a solution that is not particularly acidic or caustic (i.e., about 3 ⁇ pH ⁇ 9) and has little to no toxicity would be particularly advantageous.
- an aqueous composition adapted to kill bacteria in both planktonic and biofilm states.
- the composition also exhibits lethality toward other microbes such as viruses, fungi, molds, yeasts, and bacterial spores.
- the aqueous composition includes a significant amount of one or more surfactants and large amounts of osmotically active solutes.
- the pH of the composition preferably is moderately low (about 4 ⁇ pH ⁇ 6), although higher concentrations of acidic components can be employed.
- At least some of the osmotically active solutes include the dissociation product(s) of one or more acids that are effective at interrupting or breaking ionic crosslinks in the macromolecular matrix of the biofilm, which facilitates passage of the solutes and surfactant through the matrix to the bacteria entrained therein and/or protected thereby.
- the antimicrobial composition which is adapted for use against bacteria in a biofilm that includes a macromolecular matrix, can consist essentially of water, dissociation product(s) of one or more organic acids, and at least 1% by weight of one or more surfactants (based on the total weight of the composition).
- the composition can have an osmolarity of at least 3 Osm and a pH of no more than 6.5.
- the acid(s) can include or consist of one or more organic polyacids.
- a portion of the osmotically active solutes result from dissociation of one or more alkali metal salts of the one or more polyacids, the use of which can provide a buffered composition, i.e., a composition which resists significant changes in pH when, for example, some of the hydronium ions are consumed in the crosslink interruption just described.
- the composition includes no biocidal additives; in other words, the ingredients just described alone are sufficient to provide significant biocidal activity. Additionally or alternatively, the composition can contain no active ingredients other than acid(s) and surfactant(s).
- the aqueous composition is lethal toward planktonic and bacterial cells with high efficacy.
- it is non-toxic or, at worst, has low toxicity.
- compositions of the type described above can provide at least a 3 log reduction in the number of live bacteria after a residence time of 5 minutes.
- pH values are those which can be obtained from any of a variety of potentiometric techniques employing a properly calibrated electrode.
- a composition according to the present invention can result, after no more than 10 minutes residence time, in at least 6 log (99.9999%) reductions in the number of bacteria in an entrenched biofilm.
- Embodiments of the composition which are non-toxic if ingested can result, after no more than 10 minutes residence time, in at least 4 log (99.99%) reductions in the number of bacteria in an entrenched biofilm.
- the foregoing compare to commercially available bactericides, where non-toxic versions show less than a 1 log (90%) reduction and toxic versions show 1 to 2 log (90-99%) reductions, with the latter exhibiting a much higher level of toxicity levels than any embodiment of the presently provided composition.
- the composition can contain as few as three ingredients: water, the dissociation product(s) of at least one acid, and at least one surfactant, each of which generally is considered to be biocompatible.
- the dissociation product(s) of one or more alkali metal salts of organic acids can be included in some embodiments. Certain embodiments of the composition employ no active biocides.
- any source of water can be used, although those that are relatively free of bacteria without advance treatment are preferred.
- the water need not be distilled, deionized, etc., although such treatments certainly are not excluded.
- the water can be heated.
- composition has a pH less than 7.
- acidic protons i.e., hydronium ions
- hydronium ions are believed to be involved in breaking ionic cross-links in the macromolecular matrix of a biofilm.
- Increases in the concentration of hydronium ions generally correspond with enhanced efficacy of the composition. This effect may not be linear, i.e., the enhancement in efficacy may be asymptotic past a certain hydronium ion concentration.
- the pH of the composition is greater than ⁇ 3, the composition generally will be biocompatible; specifically, external exposure will result in no long-term negative dermal effects and ingestion can result biodegradation and/or biosorption, particularly if diluted with water soon after ingestion.
- the pH is greater than ⁇ 4
- accidental inhalation or exposure to an aerosolized version of the composition should not result in laryngospasms or other throat-related damage.
- even those embodiments of the composition having a pH below ⁇ 4 are believed to be significantly less toxic than presently available commercial products.
- the pH of the composition is less than 7 . 0 , generally less than 6 . 6 , less than 6.4, less than 6.2, less than 6.0, less than 5.8, less than 5.6, less than 5.4, less than 5.2, less than 5.0, less than 4.8, less than 4.6, less than 4.4, less than 4.2, less than 4.0, less than 3.8, less than 3.6, less than 3.6, less than 3.4, less than 3.2, or even less than 3.0; in terms of ranges, the pH of the composition can be from ⁇ 2 to ⁇ 6.7, from ⁇ 2.5 to ⁇ 6.5, from ⁇ 2.7 to ⁇ 6.3, from ⁇ 3 to ⁇ 6, from ⁇ 3.3 to ⁇ 5.7, or from ⁇ 3.5 to ⁇ 5.5.
- Acidity is achieved by adding to water (or vice versa) one or more acids, specifically strong (mineral) acids such as HCl, H 2 SO 4 , H 3 PO 4 , HNO 3 , H 3 BO 3 , and the like or, preferably, organic acids, particularly organic polyacids.
- acids specifically strong (mineral) acids such as HCl, H 2 SO 4 , H 3 PO 4 , HNO 3 , H 3 BO 3 , and the like or, preferably, organic acids, particularly organic polyacids.
- organic acids include monoprotic acids such as formic acid, acetic acid and substituted variants (e.g., hydroxy-acetic acid, chloroacetic acid, dichloroacetic acid, phenylacetic acid, and the like), propanoic acid and substituted variants (e.g., lactic acid, pyruvic acid, and the like), any of a variety of benzoic acids (e.g., mandelic acid, chloromandelic acid, salicylic acid, and the like), glucuronic acid, and the like; diprotic acids such as oxalic acid and substituted variants (e.g., oxamic acid), butanedioic acid and substituted variants (e.g., malic acid, aspartic acid, tartaric acid, citramalic acid, and the like), pentanedioic acid and substituted variants (e.g., glutamic acid, 2-ketoglutaric acid, and the like), hexanedio
- preference can be given to those organic acids which can act to chelate the metallic cations ionic involved in crosslinking the macromolecular matrix of the biofilm.
- the surfactant component can be added to water before, after or at the same time as the acid(s).
- any material having surface active properties in water can be employed, although those that bear some type of ionic charge are expected to have enhanced antimicrobial efficacy because such charges, when brought into contact with a bacteria, are believed to lead to more effective cell membrane disruption and, ultimately, to cell leakage and lysis.
- This type of antimicrobial process can kill even sessile bacteria because it does not involve or entail disruption of a cellular process.
- anionic surfactants include, but are not limited to, sodium chenodeoxycholate, N-lauroylsarcosine sodium salt, lithium dodecyl sulfate, 1-octane-sulfonic acid sodium salt, sodium cholate hydrate, sodium deoxycholate, sodium dodecyl sulfate, sodium glycodeoxycholate, sodium lauryl sulfate, and the alkyl phosphates set forth in U.S. Pat. No. 6,610,314.
- Potentially useful cationic surfactants include, but are not limited to, hexadecylpyridinium chloride monohydrate and hexadecyltrimethylammonium bromide, with the latter being a preferred material.
- Potentially useful nonionic surfactants include, but are not limited to, polyoxyethyleneglycol dodecyl ether, N-decanoyl-N-methyl-glucamine, digitonin, n-dodecyl B-D-maltoside, octyl B-D-glucopyranoside, octylphenol ethoxylate, polyoxyethylene (8) isooctyl phenyl ether, polyoxyethylene sorbitan mono-laurate, and polyoxyethylene (20) sorbitan monooleate.
- Useful zwitterionic surfactants include but are not limited to 3-[(3-cholamidopropyl) dimethylammonio]-1-propane sulfonate, 3-(decyldimethylammonio) propanesulfonate inner salt, and N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate.
- the interested reader is directed to any of a variety of other sources including, for example, U.S. Pat. Nos. 4,107,328 and 6,953,772 as well as U.S. Pat. Publ. No. 2007/0264310.
- the composition contains a sufficient amount (expressed in terms of weight/moles or concentration) of surfactant to interrupt or rupture bacterial cell walls.
- This amount can vary widely based on a variety of factors including, for example, the age of the biofilm (particularly whether it is entrenched, a factor which relates to the type of proteins and mass of the macromolecular matrix), size of the biofilm, amount of surface soiling, the species of bacteria, whether more than one type of bacteria is present, the solubility of the surfactant(s), and the like.
- the amount of surfactant generally constitutes greater than ⁇ 0.2%, typically at least ⁇ 0.5%, more typically at least ⁇ 0.7%, often at least ⁇ 0.9%, and preferably at least 1% of the composition (with all being weight percentages based on the total weight of the composition), with the upper limit being defined by the solubility limits of the particular surfactant(s) chosen.
- Some surfactants can permit extremely high loading levels, e.g., at least 5%, at least 10%, at least 12%, at least 15%, at least 17%, at least 20%, or even on the order of ⁇ 25% or more (with all being weight percentages based on the total weight of the composition). Any of the foregoing minimum amounts can be combined with any of the foregoing maximum amounts to provide an exemplary range of potential amounts of surfactant.
- the surfactant(s) can be the only antimicrobial agents in the composition, specifically, the composition can be free of active antimicrobial agents.
- the lethality of the surfactant component(s) is increased and/or enhanced when the composition has at least moderate effective solute concentrations (tonicity).
- tonicity effective solute concentrations
- compositions having higher tonicities may exert higher osmotic pressure to the bacterial cell wall, which increases its susceptibility to interruption by surfactant.
- the osmolarity of the composition generally increases in proportion with the amount of acid(s) employed, with the osmolarity maximum for a given composition primarily being a function of the solubility limits of the specific acid, i.e., the point at which the acid(s) begin to no longer be soluble.
- An obvious corollary to increased levels of acid(s) in the composition is higher concentrations of hydronium ions, i.e., low pH values.
- hydronium ions i.e., low pH values.
- some end-use applications can call for a composition with only a moderately low pH.
- one or more types of other water soluble compounds can be included. Such compounds, upon dissociation, increase the effective amount of solutes in the composition without greatly impacting the molar concentration of hydronium ions while, simultaneously, providing a buffer system in the composition.
- One approach to achieve increased tonicity of the composition is by adding large amounts of ionic compounds (salts); see, e.g., U.S. Pat. No. 7,090,882.
- ionic compounds salts
- a preferred approach to increasing tonicity involves inclusion of salt(s) of one or more the acid(s) or the salt(s) of one or more other organic acids.
- a many fold excess e.g., 3x-10x, preferably at least 5x or even at least 8x
- the identity of the countercation portion of the salt is not believed to be particularly critical, with common examples including ammonium ions and alkali metals.
- a polyacid where a polyacid is used, all or fewer than all of the carboxyl H atoms can be replaced with cationic atoms or groups, which can be the same or different.
- mono-, di- and trisodium citrate all constitute potentially useful buffer precursors.
- trisodium citrate has three available basic sites, it has a theoretical buffering capacity up to 50% greater than that of disodium citrate (which has two such sites) and up to 200% greater than that of sodium citrate (which has only one such site).
- the tonicity of the composition is at least moderately high, with an osmolarity of at least about 1 Osm being preferred for most applications.
- the composition can have any of the following concentrations: at least ⁇ 1.5 Osm, at least ⁇ 1.75 Osm, at least ⁇ 2.0 Osm, at least ⁇ 2.25 Osm, at least ⁇ 2.5 Osm, at least ⁇ 2.75 Osm, at least ⁇ 3.0 Osm, at least ⁇ 3.25 Osm, at least ⁇ 3.5 Osm, at least ⁇ 3.75 Osm, at least ⁇ 4.0 Osm, and even at least ⁇ 4.25 Osm.
- compositions can exhibit solute concentrations of 1 to 5 Osm, 1.2 to 4.5 Osm, 1.4 to 4.4 Osm, 1.6 to 4.3 Osm, 1.8 to 4.2 Osm, 1.9 to 4.1 Osm, and 2 to 4 Osm; other potentially useful ranges include 3-5 Osm, 2.5-4.5 Osm, 3-4.5 Osm, 3.5-5 Osm, 3.25-4.5 Osm, and the like.
- a biocompatible composition i.e., minimal toxicity
- a biocompatible composition can entail a pH maintained above ⁇ 4, an effective solute concentration of at least ⁇ 0.10 Osm, and large amounts of one or more surfactant(s).
- Increasing the pH to ⁇ 6 or higher can increase biocompatibility of the composition but, simultaneously, decrease its efficacy in killing microbes; conversely, decreasing the pH below ⁇ 4 and/or increasing the osmolarity of the composition can increase its antimicrobial capacity while, simultaneously, reducing its biocompatibility.
- no particular benefit is seen from reducing the amount of surfactant employed, although too high of an amount can present toxicity concerns in some circumstances.
- composition can be prepared in a number of ways. Description of an exemplary method follows.
- Acid e.g., anhydrous citric acid
- optional buffer precursor e.g., a citric acid salt such as sodium citrate dihydrate
- sufficient water to constitute ⁇ 80% of the calculated desired volume.
- This solution can be stirred and/or heated to promote solution of the acid and optional buffer precursor.
- the desired amount of surfactant(s) then can be added before additional water is added to bring the composition close to the calculated volume.
- stirring, if used, is complete sufficient water is added so as to bring the composition to the calculated value.
- no special conditions or containers are needed to store the composition for an extended time, although refrigeration can be used if desired.
- additives and adjuvants can be included to make a composition more amenable for use in a particular end-use application with negatively affecting its efficacy in a substantial manner.
- examples include, but are not limited to, emollients, fungicides, fragrances, pigments, dyes, defoamers, foaming agents, flavors, abrasives, bleaching agents, preservatives (e.g., antioxidants) and the like.
- composition does not require inclusion of an active antimicrobial agent for efficacy, but such materials can be included in certain embodiments.
- an active antimicrobial agent for efficacy, but such materials can be included in certain embodiments.
- one or more of bleach, any of a variety of phenols, aldehydes, quaternary ammonium compounds, etc. can be added.
- composition conveniently can be provided as a solution, although other forms might be desirable for certain end-use applications. Accordingly, the composition can provided as a soluble powder (for subsequent dilution, an option which can reduce transportation costs), a slurry, or a thicker form such as a gel or paste (which might be particularly useful for providing increased residence times).
- the composition can include additional ingredients such as a coalescent (e.g., polyvinylpyrrolidone).
- Embodiments of the composition can provide very large reductions in the number of bacteria, even with extremely short residence times.
- a composition having high concentrations of surfactant (e.g., 1.5-2.5% by wt.) and total solutes (e.g., 3-4 Osm) can provide a 2, 3 or 4 log (99.99%) reduction in the number of bacteria in an entrenched biofilm with a 3, 4, 5, 7, 8, 9, or 10 minute residence time and a 3, 4, 5, or 6 log (99.9999%) reduction in the number of planktonic bacteria with a mere 30-second residence time.
- Quantitative Carrier Testing (ASTM E2197) is designed to determine the contact time necessary to eradicate from a surface (e.g., countertops, sinks, bathroom fixtures, and the like) bacteria in a soil-loaded inoculum.
- a surface e.g., countertops, sinks, bathroom fixtures, and the like
- bacteria combined with a soil loading and a 10 ⁇ L inoculum is placed on a stainless steel carrier disk.
- 50 ⁇ L of antimicrobial treatment composition is applied and allowed to stay in place for the desired treatment time, after which dilution with a saline dilution is performed.
- the following are results achieved from Quantitative Carrier Testing using 5% soil load and a 3 minute residence time (with TDTMAB representing tetradecyltrimethylammonium bromide):
- An alternative test designed to show efficacy against an entrenched biofilm involves treatment of biofilm-forming bacterial strains grown over several days (typically in an incubator at 37° C. and aerobic conditions) in a drip-flow reactor, designed to model growth in a low shear environment.
- Bacteria are inoculated (e.g., on glass slides, optionally coated with hydroxyapatite) pre-coated with a sterile medium (e.g., trypticase soy broth).
- a coated slide then is inoculated with a culture of the biofilm-forming microbe of interest.
- the reactor is placed in a horizontal position (typically ⁇ 2 hours) to promote bacterial attachment to the substrate before being inclined (e.g., to a 10° angle), with sterile medium dripping on the slides (typically at a rate of ⁇ 2.78 ⁇ 10 ⁇ 3 mL/sec). After a desired number of days of growth, flow of the sterile medium is halted, and the reactor is raised to horizontal. Antimicrobial composition is applied, while a control slide is treated with saline solution. After an amount of time (typically 5-10 minutes), the slides are rinsed with saline solution.
- the foregoing data includes much of interest including, for example, a potential indication that pseudomonas, a gram negative bacteria, is more affected by the osmolarity of the composition than by the type or concentration of surfactant employed, while the opposite might be true for staph.
- the composition can be employed in a variety of ways. For example, when used to treat a biofilm on a surface (e.g., cutting board, counter, desk, etc.), the composition can be applied directly to the biofilm, optionally followed by physical rubbing or buffing, or the composition can be applied to the rubbing/buffing medium, e.g., cloth. Where a biofilm in an inaccessible area is to be treated, soaking or immersion of the biofilm in an excess of the composition can be performed for a time sufficient to essentially solvate the biofilm, which then can be flushed from the affected area. Regardless of contact method, the surfactant component(s) are believed to kill significant numbers of bacteria without a need for the bacteria to be removed from the biofilm or vice versa.
- the composition may find utility in a large number of potential uses including, but not limited to, household applications including non-compromised skin (hand, hair, and body washing), kitchen cleaning (countertop and surface cleaning, cleaning of food preparation utensils, dish washing, produce washing, etc.), bathroom cleaning (countertop and surface cleaning, fixture cleaning, toilet bowl cleaning and shower mildew eradication), and laundry area cleaning (including laundry detergent and diaper sterilization); commercial applications include livestock care (facility and equipment sterilization and dairy teat dip), produce sterilization (an alternative to irradiation, which can be particularly useful against e-coli, listeria, salmonella, Botulism , etc.), commercial kitchen (countertop and surface cleaning, food preparation utensil cleaning, storage equipment and facilities cleaning, dish washing and produce washing), mass food and beverage processing (processing and storage equipment cleaning, tank sterilization, cleaning of liquid transport lines, etc.), cleaning of water lines (e.g., for drinking water, dental offices, plumbing, and the like), and food and beverage transport
- household applications including non-comprom
Landscapes
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Toxicology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
- This application is a division of U.S. patent application Ser. No. 13/679,994 filed 16 Nov. 2012, presently pending, which is a continuation of U.S. patent application Ser. No. 12/573,340 filed 5 Oct. 2009, presently pending, which claimed the benefit of U.S. provisional application no. 61/103,214 filed 6 Oct. 2008, the entire disclosures of which are incorporated herein by reference.
- Bacteria is found virtually everywhere and is responsible for a significant amount of disease and infection. Ridding surfaces of bacteria is desirable to reduce human exposure. Bacteria in normal environments have developed self preservation mechanisms and are therefore extremely difficult to remove and/or eradicate.
- Bacteria can be found in both planktonic and biofilm forms. In the biofilm form, they interact with surfaces and form surface colonies which adhere to a surface and continue to grow. The bacteria produce exopolysaccharide (EPS) and/or extracellularpoly-saccharide (ECPS) macromolecules that keep them attached to the surface and form a protective film that is effective against many forms of attack. Protection most likely can be attributed to the small diameter of the flow channels in the matrix, which restricts the size of molecules that can transport to the underlying bacteria, and consumption of biocides through interactions with portions of the EPS/ECPS macromolecular matrix.
- Additionally, the bacteria in biofilm form are down-regulated (sessile) and not actively dividing. This makes them resistant to attack by a large group of antibiotics and antimicrobials, which attack the bacteria during the active parts of their lifecycle, e.g., cell division.
- Due to the protection afforded by the macromolecular matrix and their down-regulated state, bacteria in a biofilm are very difficult to treat. The types of biocides and antimicrobials that are effective in treating bacteria in this form are strongly acidic, oxidizing, and toxic, often involving halogen atoms, oxygen atoms, or both. Common examples include concentrated bleach, strong mineral acids (e.g., HCl) and hydrogen peroxide. Commonly, large dosages of such chemicals are allowed to contact the biofilm for extended amounts of time (up to 24 hours in some circumstances), which makes them impractical for many applications.
- Recent developments have involved formulations intended for use against compromised animal/human tissue which, accordingly, are intentionally gentle so as to prevent damage or irritation to compromised tissue. These formulations solvate the bio-film matrix so that still-living bacteria can be rinsed or otherwise removed from infected tissue. The concentrations of active ingredients in these formulations are too low to effectively kill the bacteria in the biofilm, and are thus ill suited for surface disinfection.
- A solution that can disrupt the macromolecular matrix, or bypass and/or disable the defenses inherent in these matrices, allowing lethal doses of the antimicrobial ingredients in the solution to access and kill the bacteria in their biofilm and sessile states, remains desirable. Such a solution that is not particularly acidic or caustic (i.e., about 3≦pH≦9) and has little to no toxicity would be particularly advantageous.
- Provided herein is an aqueous composition adapted to kill bacteria in both planktonic and biofilm states. In addition to being lethal toward a wide spectrum of gram positive and gram negative bacteria, the composition also exhibits lethality toward other microbes such as viruses, fungi, molds, yeasts, and bacterial spores.
- Broadly, the aqueous composition includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. The pH of the composition preferably is moderately low (about 4≦pH≦6), although higher concentrations of acidic components can be employed. At least some of the osmotically active solutes include the dissociation product(s) of one or more acids that are effective at interrupting or breaking ionic crosslinks in the macromolecular matrix of the biofilm, which facilitates passage of the solutes and surfactant through the matrix to the bacteria entrained therein and/or protected thereby.
- The antimicrobial composition, which is adapted for use against bacteria in a biofilm that includes a macromolecular matrix, can consist essentially of water, dissociation product(s) of one or more organic acids, and at least 1% by weight of one or more surfactants (based on the total weight of the composition). The composition can have an osmolarity of at least 3 Osm and a pH of no more than 6.5.
- In certain embodiments of the foregoing, the acid(s) can include or consist of one or more organic polyacids.
- In at least some embodiments, a portion of the osmotically active solutes result from dissociation of one or more alkali metal salts of the one or more polyacids, the use of which can provide a buffered composition, i.e., a composition which resists significant changes in pH when, for example, some of the hydronium ions are consumed in the crosslink interruption just described.
- In at least some embodiments, the composition includes no biocidal additives; in other words, the ingredients just described alone are sufficient to provide significant biocidal activity. Additionally or alternatively, the composition can contain no active ingredients other than acid(s) and surfactant(s).
- Without wishing to be bound by theory, the combination of high tonicity (high osmolar concentration) and large amounts of surfactant is believed to induce bacterial membrane leakage, leading to cell lysis. While the ingredients used to prepare such compositions typically are ineffective as bactericides when used at concentrations commonly employed in commercial products, an appropriately formulated composition has been found to be very effective at breaking down or bypassing and disabling biofilm defenses, thereby allowing the composition to access and kill the bacteria, even when it is in a sessile state.
- The aqueous composition is lethal toward planktonic and bacterial cells with high efficacy. Advantageously, in many embodiments, it is non-toxic or, at worst, has low toxicity.
- Also provided are methods of making and using the foregoing composition. In at least one such method, application of a composition of the type described above to a biofilm can provide at least a 3 log reduction in the number of live bacteria after a residence time of 5 minutes.
- To assist in understanding the following description of various embodiments, certain definitions are provided immediately below. These are intended to apply through-out unless the surrounding text explicitly indicates a contrary intention:
-
- “microbe” means any type of microorganism including, but not limited to, bacteria, viruses, fungi, viroids, prions, and the like;
- “antimicrobial agent” means a substance having the ability to cause greater than a 90% (1 log) reduction, preferably at least a 99% (2 log) reduction in the number of one or more of microbes including, but not limited to, bacteria selected from Staphylococcus aureus and Pseudomonas aeruginosa;
- “active antimicrobial agent” means an antimicrobial agent that is effective only or primarily during the active parts of the lifecycle, e.g., cell division, of a microbe;
- “biofilm” means a community of microbes, particularly bacteria and fungi, attached to a surface with the community members being contained in and/or protected by a self-generated macromolecular matrix;
- “residence time” means the amount of time that an antimicrobial agent is allowed to contact a bacterial biofilm;
- “entrenched biofilm” is a biofilm that has reached a steady state mass after a growth period of two or more days;
- “buffer” means a compound or mixture of compounds having an ability to maintain the pH of a solution to which it is added within relatively narrow limits;
- “buffer precursor” means a compound that, when added to a mixture containing an acid, results in a buffer;
- “polyacid” means a compound having at least two carboxyl groups and specifically includes dicarboxylic acids, tricarboxylic acids, etc.;
- “biocompatible” means presenting no significant, long-term deleterious effects on or in a mammalian species;
- “biodegradation” means transformation, via enzymatic, chemical or physical in vivo processes, of a chemical into smaller chemical species;
- “biosorption” means absorption of a material into the body of a mammalian species;
- “soil load” means a solution of one or more organic and/or inorganic substances added to the suspension of a test organism to simulate the presence of body secretions, excretions, and the like; and
- “inoculum” means a solution containing bacteria, growth solution (e.g., tryptic soy broth) and protein soil load.
- Hereinthroughout, pH values are those which can be obtained from any of a variety of potentiometric techniques employing a properly calibrated electrode.
- The relevant portion(s) of any specifically referenced patent and/or published patent application is/are incorporated herein by reference.
- A composition according to the present invention can result, after no more than 10 minutes residence time, in at least 6 log (99.9999%) reductions in the number of bacteria in an entrenched biofilm. Embodiments of the composition which are non-toxic if ingested can result, after no more than 10 minutes residence time, in at least 4 log (99.99%) reductions in the number of bacteria in an entrenched biofilm. The foregoing compare to commercially available bactericides, where non-toxic versions show less than a 1 log (90%) reduction and toxic versions show 1 to 2 log (90-99%) reductions, with the latter exhibiting a much higher level of toxicity levels than any embodiment of the presently provided composition.
- The composition can contain as few as three ingredients: water, the dissociation product(s) of at least one acid, and at least one surfactant, each of which generally is considered to be biocompatible. The dissociation product(s) of one or more alkali metal salts of organic acids can be included in some embodiments. Certain embodiments of the composition employ no active biocides.
- Essentially any source of water can be used, although those that are relatively free of bacteria without advance treatment are preferred. The water need not be distilled, deionized, etc., although such treatments certainly are not excluded. To enhance solubility of one or more of the other components of the composition, the water can be heated.
- The composition has a pH less than 7. Without wishing to be bound by theory, acidic protons (i.e., hydronium ions) are believed to be involved in breaking ionic cross-links in the macromolecular matrix of a biofilm.
- Increases in the concentration of hydronium ions, i.e., reductions in pH, generally correspond with enhanced efficacy of the composition. This effect may not be linear, i.e., the enhancement in efficacy may be asymptotic past a certain hydronium ion concentration. As long as the pH of the composition is greater than ˜3, the composition generally will be biocompatible; specifically, external exposure will result in no long-term negative dermal effects and ingestion can result biodegradation and/or biosorption, particularly if diluted with water soon after ingestion. If the pH is greater than ˜4, accidental inhalation or exposure to an aerosolized version of the composition should not result in laryngospasms or other throat-related damage. However, even those embodiments of the composition having a pH below ˜4 are believed to be significantly less toxic than presently available commercial products.
- The pH of the composition is less than 7.0, generally less than 6.6, less than 6.4, less than 6.2, less than 6.0, less than 5.8, less than 5.6, less than 5.4, less than 5.2, less than 5.0, less than 4.8, less than 4.6, less than 4.4, less than 4.2, less than 4.0, less than 3.8, less than 3.6, less than 3.6, less than 3.4, less than 3.2, or even less than 3.0; in terms of ranges, the pH of the composition can be from ˜2 to ˜6.7, from ˜2.5 to ˜6.5, from ˜2.7 to ˜6.3, from ˜3 to ˜6, from ˜3.3 to ˜5.7, or from ˜3.5 to ˜5.5.
- Acidity is achieved by adding to water (or vice versa) one or more acids, specifically strong (mineral) acids such as HCl, H2SO4, H3PO4, HNO3, H3BO3, and the like or, preferably, organic acids, particularly organic polyacids. Examples of organic acids include monoprotic acids such as formic acid, acetic acid and substituted variants (e.g., hydroxy-acetic acid, chloroacetic acid, dichloroacetic acid, phenylacetic acid, and the like), propanoic acid and substituted variants (e.g., lactic acid, pyruvic acid, and the like), any of a variety of benzoic acids (e.g., mandelic acid, chloromandelic acid, salicylic acid, and the like), glucuronic acid, and the like; diprotic acids such as oxalic acid and substituted variants (e.g., oxamic acid), butanedioic acid and substituted variants (e.g., malic acid, aspartic acid, tartaric acid, citramalic acid, and the like), pentanedioic acid and substituted variants (e.g., glutamic acid, 2-ketoglutaric acid, and the like), hexanedioic acid and substituted variants (e.g., mucic acid), butenedioic acid (both cis and trans isomers), iminodiacetic acid, phthalic acid, and the like; triprotic acids such as citric acid, 2-methylpropane-1,2,3-tricarboxylic acid, benzenetricarboxylic acid, nitrilotriacetic acid, and the like; tetraprotic acids such as prehnitic acid, pyromellitic acid, and the like; and even higher degree acids (e.g., penta-, hexa-, heptaprotic, etc.). Where a tri-, tetra-, or higher acid is used, one or more of the carboxyl protons can be replaced by cationic atoms or groups (e.g., alkali metal ions), which can be the same or different.
- In certain embodiments, preference can be given to those organic acids which are, or can be made to be, highly soluble in water; acids that include groups that enhance solubility in water (e.g., hydroxyl groups), examples of which include tartaric acid, citric acid, and citramalic acid, can be preferred in some circumstances. In these and/or other embodiments, preference can be given to those organic acids which are biocompatible; many of the organic acids listed above are used in preparing or treating food products, personal care products, and the like. Alternatively or additionally, preference can be given to those organic acids which can act to chelate the metallic cations ionic involved in crosslinking the macromolecular matrix of the biofilm.
- The surfactant component can be added to water before, after or at the same time as the acid(s).
- Essentially any material having surface active properties in water can be employed, although those that bear some type of ionic charge are expected to have enhanced antimicrobial efficacy because such charges, when brought into contact with a bacteria, are believed to lead to more effective cell membrane disruption and, ultimately, to cell leakage and lysis. This type of antimicrobial process can kill even sessile bacteria because it does not involve or entail disruption of a cellular process.
- Potentially useful anionic surfactants include, but are not limited to, sodium chenodeoxycholate, N-lauroylsarcosine sodium salt, lithium dodecyl sulfate, 1-octane-sulfonic acid sodium salt, sodium cholate hydrate, sodium deoxycholate, sodium dodecyl sulfate, sodium glycodeoxycholate, sodium lauryl sulfate, and the alkyl phosphates set forth in U.S. Pat. No. 6,610,314. Potentially useful cationic surfactants include, but are not limited to, hexadecylpyridinium chloride monohydrate and hexadecyltrimethylammonium bromide, with the latter being a preferred material. Potentially useful nonionic surfactants include, but are not limited to, polyoxyethyleneglycol dodecyl ether, N-decanoyl-N-methyl-glucamine, digitonin, n-dodecyl B-D-maltoside, octyl B-D-glucopyranoside, octylphenol ethoxylate, polyoxyethylene (8) isooctyl phenyl ether, polyoxyethylene sorbitan mono-laurate, and polyoxyethylene (20) sorbitan monooleate. Useful zwitterionic surfactants include but are not limited to 3-[(3-cholamidopropyl) dimethylammonio]-1-propane sulfonate, 3-(decyldimethylammonio) propanesulfonate inner salt, and N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate. For other potentially useful materials, the interested reader is directed to any of a variety of other sources including, for example, U.S. Pat. Nos. 4,107,328 and 6,953,772 as well as U.S. Pat. Publ. No. 2007/0264310.
- The composition contains a sufficient amount (expressed in terms of weight/moles or concentration) of surfactant to interrupt or rupture bacterial cell walls. This amount can vary widely based on a variety of factors including, for example, the age of the biofilm (particularly whether it is entrenched, a factor which relates to the type of proteins and mass of the macromolecular matrix), size of the biofilm, amount of surface soiling, the species of bacteria, whether more than one type of bacteria is present, the solubility of the surfactant(s), and the like. The amount of surfactant generally constitutes greater than ˜0.2%, typically at least ˜0.5%, more typically at least ˜0.7%, often at least ˜0.9%, and preferably at least 1% of the composition (with all being weight percentages based on the total weight of the composition), with the upper limit being defined by the solubility limits of the particular surfactant(s) chosen. Some surfactants can permit extremely high loading levels, e.g., at least 5%, at least 10%, at least 12%, at least 15%, at least 17%, at least 20%, or even on the order of ˜25% or more (with all being weight percentages based on the total weight of the composition). Any of the foregoing minimum amounts can be combined with any of the foregoing maximum amounts to provide an exemplary range of potential amounts of surfactant.
- In certain embodiments, the surfactant(s) can be the only antimicrobial agents in the composition, specifically, the composition can be free of active antimicrobial agents.
- The lethality of the surfactant component(s) is increased and/or enhanced when the composition has at least moderate effective solute concentrations (tonicity). (In biological applications, a 0.9% (by wt.) saline solution, which is ˜0.3 Osm, typically is considered to be have moderate tonicity, while a 3% (by wt.) saline solution, which is ˜0.9 Osm, generally is considered to be hypertonic.) Without wishing to be bound by theory, compositions having higher tonicities may exert higher osmotic pressure to the bacterial cell wall, which increases its susceptibility to interruption by surfactant.
- The osmolarity of the composition generally increases in proportion with the amount of acid(s) employed, with the osmolarity maximum for a given composition primarily being a function of the solubility limits of the specific acid, i.e., the point at which the acid(s) begin to no longer be soluble. An obvious corollary to increased levels of acid(s) in the composition is higher concentrations of hydronium ions, i.e., low pH values. As noted previously, some end-use applications can call for a composition with only a moderately low pH. To increase the osmolarity of a composition without depressing its pH past a desired target, one or more types of other water soluble compounds can be included. Such compounds, upon dissociation, increase the effective amount of solutes in the composition without greatly impacting the molar concentration of hydronium ions while, simultaneously, providing a buffer system in the composition.
- One approach to achieve increased tonicity of the composition is by adding large amounts of ionic compounds (salts); see, e.g., U.S. Pat. No. 7,090,882. Where one or more organic acids are used in the composition, a preferred approach to increasing tonicity involves inclusion of salt(s) of one or more the acid(s) or the salt(s) of one or more other organic acids. For example, where the composition includes x moles of an acid, a many fold excess (e.g., 3x-10x, preferably at least 5x or even at least 8x) of one or more salts of that acid also can be included. The identity of the countercation portion of the salt is not believed to be particularly critical, with common examples including ammonium ions and alkali metals. Where a polyacid is used, all or fewer than all of the carboxyl H atoms can be replaced with cationic atoms or groups, which can be the same or different. For example, mono-, di- and trisodium citrate all constitute potentially useful buffer precursors. However, because trisodium citrate has three available basic sites, it has a theoretical buffering capacity up to 50% greater than that of disodium citrate (which has two such sites) and up to 200% greater than that of sodium citrate (which has only one such site).
- Regardless of how achieved, the tonicity of the composition is at least moderately high, with an osmolarity of at least about 1 Osm being preferred for most applications. Depending on particular end-use application, the composition can have any of the following concentrations: at least ˜1.5 Osm, at least ˜1.75 Osm, at least ˜2.0 Osm, at least ˜2.25 Osm, at least ˜2.5 Osm, at least ˜2.75 Osm, at least ˜3.0 Osm, at least ˜3.25 Osm, at least ˜3.5 Osm, at least ˜3.75 Osm, at least ˜4.0 Osm, and even at least ˜4.25 Osm. Certain embodiments of the composition can exhibit solute concentrations of 1 to 5 Osm, 1.2 to 4.5 Osm, 1.4 to 4.4 Osm, 1.6 to 4.3 Osm, 1.8 to 4.2 Osm, 1.9 to 4.1 Osm, and 2 to 4 Osm; other potentially useful ranges include 3-5 Osm, 2.5-4.5 Osm, 3-4.5 Osm, 3.5-5 Osm, 3.25-4.5 Osm, and the like.
- While the characteristics of the acid(s), surfactant(s) and optional (non-acid) water soluble compounds have been described in isolation, combinations of individual values or ranges for one component can be provided in conjunction with values or ranges for one or both of the other components. For example, a biocompatible composition (i.e., minimal toxicity) can entail a pH maintained above ˜4, an effective solute concentration of at least ˜0.10 Osm, and large amounts of one or more surfactant(s). Increasing the pH to ˜6 or higher can increase biocompatibility of the composition but, simultaneously, decrease its efficacy in killing microbes; conversely, decreasing the pH below ˜4 and/or increasing the osmolarity of the composition can increase its antimicrobial capacity while, simultaneously, reducing its biocompatibility. Generally, no particular benefit is seen from reducing the amount of surfactant employed, although too high of an amount can present toxicity concerns in some circumstances.
- The composition can be prepared in a number of ways. Description of an exemplary method follows.
- Acid (e.g., anhydrous citric acid), optional buffer precursor (e.g., a citric acid salt such as sodium citrate dihydrate), and sufficient water to constitute ˜80% of the calculated desired volume. This solution can be stirred and/or heated to promote solution of the acid and optional buffer precursor. The desired amount of surfactant(s) then can be added before additional water is added to bring the composition close to the calculated volume. Once stirring, if used, is complete, sufficient water is added so as to bring the composition to the calculated value. Advantageously, no special conditions or containers are needed to store the composition for an extended time, although refrigeration can be used if desired.
- A variety of additives and adjuvants can be included to make a composition more amenable for use in a particular end-use application with negatively affecting its efficacy in a substantial manner. Examples include, but are not limited to, emollients, fungicides, fragrances, pigments, dyes, defoamers, foaming agents, flavors, abrasives, bleaching agents, preservatives (e.g., antioxidants) and the like.
- The composition does not require inclusion of an active antimicrobial agent for efficacy, but such materials can be included in certain embodiments. For example, one or more of bleach, any of a variety of phenols, aldehydes, quaternary ammonium compounds, etc., can be added.
- The composition conveniently can be provided as a solution, although other forms might be desirable for certain end-use applications. Accordingly, the composition can provided as a soluble powder (for subsequent dilution, an option which can reduce transportation costs), a slurry, or a thicker form such as a gel or paste (which might be particularly useful for providing increased residence times). For the latter, the composition can include additional ingredients such as a coalescent (e.g., polyvinylpyrrolidone).
- Embodiments of the composition can provide very large reductions in the number of bacteria, even with extremely short residence times. For example, a composition having high concentrations of surfactant (e.g., 1.5-2.5% by wt.) and total solutes (e.g., 3-4 Osm) can provide a 2, 3 or 4 log (99.99%) reduction in the number of bacteria in an entrenched biofilm with a 3, 4, 5, 7, 8, 9, or 10 minute residence time and a 3, 4, 5, or 6 log (99.9999%) reduction in the number of planktonic bacteria with a mere 30-second residence time.
- Quantitative Carrier Testing (ASTM E2197) is designed to determine the contact time necessary to eradicate from a surface (e.g., countertops, sinks, bathroom fixtures, and the like) bacteria in a soil-loaded inoculum. In this test, bacteria combined with a soil loading and a 10 μL inoculum is placed on a stainless steel carrier disk. After the inoculate is allowed to dry completely, 50 μL of antimicrobial treatment composition is applied and allowed to stay in place for the desired treatment time, after which dilution with a saline dilution is performed. The following are results achieved from Quantitative Carrier Testing using 5% soil load and a 3 minute residence time (with TDTMAB representing tetradecyltrimethylammonium bromide):
-
- 0.021 M caprylyl sulfobetaine, 3.2 Osm, 6.5 pH—5.2 log reduction of pseudomonas
- 0.028 M caprylyl sulfobetaine, 3.6 Osm, 5.5 pH—3.1 log reduction of staph and 5.9 log reduction of pseudomonas
- 0.041 M TDTMAB, 3.5 Osm, 6.5 pH—5.1 log reduction of staph and 7.5 log reduction of pseudomonas
- 0.027 M TDTMAB, 3.5 Osm, 6.5 pH—4.9 log reduction of staph and 5.2 log reduction of pseudomonas
- 0.041 M TDTMAB, 1.8 Osm, 6.5 pH—3.2 log reduction of staph and 5.2 log reduction of pseudomonas
- 0.027 M TDTMAB, 1.8 Osm, 6.5 pH—3.2 log reduction of staph and 4.7 log reduction of pseudomonas
- 0.014 M TDTMAB, 1.8 Osm, 6.5 pH—2.9 log reduction of staph and 4.5 log reduction of pseudomonas
Where the third composition was used again at a one-minute residence time, the results were a 5.1 log reduction of staph (i.e., no change, indicating that much of the killing of staph bacteria may occur in the first minute), and a 6.8 log reduction of pseudomonas.
- An alternative test designed to show efficacy against an entrenched biofilm involves treatment of biofilm-forming bacterial strains grown over several days (typically in an incubator at 37° C. and aerobic conditions) in a drip-flow reactor, designed to model growth in a low shear environment. Bacteria are inoculated (e.g., on glass slides, optionally coated with hydroxyapatite) pre-coated with a sterile medium (e.g., trypticase soy broth). A coated slide then is inoculated with a culture of the biofilm-forming microbe of interest. The reactor is placed in a horizontal position (typically ˜2 hours) to promote bacterial attachment to the substrate before being inclined (e.g., to a 10° angle), with sterile medium dripping on the slides (typically at a rate of ˜2.78×10−3 mL/sec). After a desired number of days of growth, flow of the sterile medium is halted, and the reactor is raised to horizontal. Antimicrobial composition is applied, while a control slide is treated with saline solution. After an amount of time (typically 5-10 minutes), the slides are rinsed with saline solution. Each slide is removed and placed in a sterile container, scraped, vortexed, and sonicated multiple times to harvest bacteria which are then incubated on plates for counting. Efficacy is calculated by subtracting the bacterial count on a treated slide from the bacterial count on a control (non-treated) slide. The following are results achieved from this test using a 5 minute residence time:
-
- 0.028 M caprylyl sulfobetaine, 3.5 Osm, 6.5 pH—2.8 log reduction of staph and 6.0 log reduction of pseudomonas
- 0.023 M octyl sulfobetaine, 3.5 Osm, 6.5 pH—1.4 log reduction of staph and 6.2 log reduction of pseudomonas
- 0.016 M TDTMAB, 0.8 Osm, 6.5 pH—3.0 log reduction of staph and 2.2 log reduction of pseudomonas
- 0.041 M TDTMAB, 3.5 Osm, 6.5 pH—8.9 log reduction of staph and 6.7 log reduction of pseudomonas
- The foregoing data includes much of interest including, for example, a potential indication that pseudomonas, a gram negative bacteria, is more affected by the osmolarity of the composition than by the type or concentration of surfactant employed, while the opposite might be true for staph.
- The foregoing levels of bactericidal activity are greater than for most strong chemical treatments in current use, even though the composition is far less toxic (i.e., more biocompatible) than those treatments. Generally, longer residence times can result in greater reductions in the number of bacteria, although the effect may be asymptotic.
- The composition can be employed in a variety of ways. For example, when used to treat a biofilm on a surface (e.g., cutting board, counter, desk, etc.), the composition can be applied directly to the biofilm, optionally followed by physical rubbing or buffing, or the composition can be applied to the rubbing/buffing medium, e.g., cloth. Where a biofilm in an inaccessible area is to be treated, soaking or immersion of the biofilm in an excess of the composition can be performed for a time sufficient to essentially solvate the biofilm, which then can be flushed from the affected area. Regardless of contact method, the surfactant component(s) are believed to kill significant numbers of bacteria without a need for the bacteria to be removed from the biofilm or vice versa.
- Due to the abundance of microbial contamination, the composition may find utility in a large number of potential uses including, but not limited to, household applications including non-compromised skin (hand, hair, and body washing), kitchen cleaning (countertop and surface cleaning, cleaning of food preparation utensils, dish washing, produce washing, etc.), bathroom cleaning (countertop and surface cleaning, fixture cleaning, toilet bowl cleaning and shower mildew eradication), and laundry area cleaning (including laundry detergent and diaper sterilization); commercial applications include livestock care (facility and equipment sterilization and dairy teat dip), produce sterilization (an alternative to irradiation, which can be particularly useful against e-coli, listeria, salmonella, Botulism, etc.), commercial kitchen (countertop and surface cleaning, food preparation utensil cleaning, storage equipment and facilities cleaning, dish washing and produce washing), mass food and beverage processing (processing and storage equipment cleaning, tank sterilization, cleaning of liquid transport lines, etc.), cleaning of water lines (e.g., for drinking water, dental offices, plumbing, and the like), and food and beverage transport (cleaning of tanker units for semi transport, cleaning of tanker cars for railroad transport, and cleaning of pipelines); and non-traditional uses such as denture cleaning, acne treatment, spermicides, laboratory equipment cleaning, laboratory surface cleaning, oil pipeline cleaning, and test article processing for biofilm attachment.
- While various embodiments of the present invention have been provided, they are presented by way of example and not limitation. The following claims and their equivalents define the breadth and scope of the inventive methods and compositions, and the same are not to be limited by or to any of the foregoing exemplary embodiments.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/847,876 US20130272922A1 (en) | 2008-10-06 | 2013-03-20 | Antimicrobial composition and methods for using same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10321408P | 2008-10-06 | 2008-10-06 | |
US12/573,340 US20100086576A1 (en) | 2008-10-06 | 2009-10-05 | Antimicrobial composition and methods of making and using same |
US13/679,994 US8940792B2 (en) | 2008-10-06 | 2012-11-16 | Antimicrobial composition and methods for using same |
US13/847,876 US20130272922A1 (en) | 2008-10-06 | 2013-03-20 | Antimicrobial composition and methods for using same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/679,994 Division US8940792B2 (en) | 2008-10-06 | 2012-11-16 | Antimicrobial composition and methods for using same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130272922A1 true US20130272922A1 (en) | 2013-10-17 |
Family
ID=42076001
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/573,340 Abandoned US20100086576A1 (en) | 2008-10-06 | 2009-10-05 | Antimicrobial composition and methods of making and using same |
US13/679,994 Active US8940792B2 (en) | 2008-10-06 | 2012-11-16 | Antimicrobial composition and methods for using same |
US13/847,876 Abandoned US20130272922A1 (en) | 2008-10-06 | 2013-03-20 | Antimicrobial composition and methods for using same |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/573,340 Abandoned US20100086576A1 (en) | 2008-10-06 | 2009-10-05 | Antimicrobial composition and methods of making and using same |
US13/679,994 Active US8940792B2 (en) | 2008-10-06 | 2012-11-16 | Antimicrobial composition and methods for using same |
Country Status (3)
Country | Link |
---|---|
US (3) | US20100086576A1 (en) |
EP (1) | EP2346324A4 (en) |
WO (1) | WO2010042427A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017069820A2 (en) | 2015-07-17 | 2017-04-27 | Next Science, Llc | Antimicrobial composition having efficacy against endospores |
WO2022147055A1 (en) * | 2020-12-29 | 2022-07-07 | Next Science IP Holdings Pty Ltd | Cancer treatment composition and method |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100086576A1 (en) | 2008-10-06 | 2010-04-08 | Myntti Matthew F | Antimicrobial composition and methods of making and using same |
CA2835211C (en) * | 2011-05-10 | 2019-09-24 | Next Science, Llc | Antimicrobial solid and methods of making and using same |
US9872843B2 (en) | 2011-10-08 | 2018-01-23 | Next Science, Llc | Antimicrobial compositions and methods employing same |
WO2014155147A2 (en) | 2012-01-18 | 2014-10-02 | Nch Corporation | Composition, system, and method for treating water systems |
US9707520B2 (en) | 2012-01-18 | 2017-07-18 | Nch Corporation | Composition, system, and method for treating water systems |
US20130338227A1 (en) | 2012-06-13 | 2013-12-19 | Marie-Esther Saint Victor | Green Glycine Betaine Derivative Compounds And Compositions Containing Same |
EP2991483A4 (en) * | 2013-05-02 | 2016-11-30 | Next Science Llc | High osmolarity antimicrobial composition containing one or more organic solvents |
US9441190B2 (en) | 2013-11-06 | 2016-09-13 | Nch Corporation | Composition and method for treating water systems |
US9506016B2 (en) | 2013-11-06 | 2016-11-29 | Nch Corporation | Composition and method for treating water systems |
WO2017027418A1 (en) * | 2015-08-07 | 2017-02-16 | Next Science, Llc | Antimicrobial composition having efficacy against endospores |
CA3029601A1 (en) | 2016-06-30 | 2018-01-04 | Next Science IP Holdings Pty Ltd | Antimicrobial compositions and methods employing same |
WO2019099932A1 (en) | 2017-11-19 | 2019-05-23 | Next Science IP Holdings Pty Ltd | Compositions and methods for treating intervertebral discs |
US11419333B2 (en) * | 2018-01-19 | 2022-08-23 | Championx Usa Inc. | Compositions and methods for biofilm removal |
AU2021362201A1 (en) * | 2020-10-14 | 2023-03-23 | Next Science IP Holdings Pty Ltd | Methods and compositions useful for reducing bioburden in wounds |
US11672773B2 (en) * | 2020-12-13 | 2023-06-13 | Next Science IP Holdings Pty Ltd | Methods for treating ciliated cavities |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6149822A (en) * | 1999-03-01 | 2000-11-21 | Polymer Ventures, Inc. | Bio-film control |
US6701940B2 (en) * | 2001-10-11 | 2004-03-09 | S. C. Johnson & Son, Inc. | Hard surface cleaners containing ethylene oxide/propylene oxide block copolymer surfactants |
US20080274932A1 (en) * | 2007-05-04 | 2008-11-06 | Ecolab Inc. | Composition for in situ manufacture of insoluble hydroxide when cleaning hard surfaces and for use in automatic warewashing machines and methods for manufacturing and using |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB983130A (en) * | 1962-08-06 | 1965-02-10 | Mundipharma Ag | Improvements in preparations for the removal of wax from the ear |
US4002775A (en) * | 1973-07-09 | 1977-01-11 | Kabara Jon J | Fatty acids and derivatives of antimicrobial agents |
US4067997A (en) * | 1975-05-21 | 1978-01-10 | Med-Chem Laboratories | Synergistic microbecidal composition and method |
JPS527428A (en) * | 1975-07-09 | 1977-01-20 | Riken Vitamin Co Ltd | Method for preserving foods |
CA1052273A (en) * | 1975-12-18 | 1979-04-10 | Edwin B. Michaels | Antimicrobial compositions |
US4323551A (en) * | 1981-02-19 | 1982-04-06 | The Procter & Gamble Company | Mouthwash compositions |
US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
US5208257A (en) * | 1986-04-21 | 1993-05-04 | Kabara Jon J | Topical antimicrobial pharmaceutical compositions and methods |
US5017229A (en) * | 1990-06-25 | 1991-05-21 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
US5290552A (en) * | 1988-05-02 | 1994-03-01 | Matrix Pharmaceutical, Inc./Project Hear | Surgical adhesive material |
IT1219587B (en) * | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES |
US5575815A (en) * | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
CA2019719A1 (en) * | 1990-06-25 | 1991-12-25 | William J. Thompson | Mouthwash |
EP0466397A3 (en) * | 1990-07-10 | 1992-05-06 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo | Treatment of inflammatory diseases with polyoxyethylenesorbitan mono-higher-fatty acid esters |
US5662913A (en) * | 1991-04-10 | 1997-09-02 | Capelli; Christopher C. | Antimicrobial compositions useful for medical applications |
AU656384B2 (en) * | 1991-04-10 | 1995-02-02 | Christopher C. Capelli | Antimicrobial compositions useful for medical applications |
US5326492A (en) | 1991-11-18 | 1994-07-05 | Medical Polymers, Inc. | Disinfectant mixture containing water soluble lubricating and cleaning agents and method |
US5229103A (en) * | 1992-04-30 | 1993-07-20 | Hydrodent Laboratories, Inc. | Antiplaque mouthwash concentrate |
IT1260154B (en) * | 1992-07-03 | 1996-03-28 | Lanfranco Callegaro | HYALURONIC ACID AND ITS DERIVATIVES IN INTERPENETRATING POLYMERS (IPN) |
GB9218834D0 (en) | 1992-09-05 | 1992-10-21 | Procter & Gamble | Nasal spray products |
CN1091315A (en) * | 1992-10-08 | 1994-08-31 | E·R·斯奎布父子公司 | Fibrin sealant compositions and using method thereof |
US5362442A (en) * | 1993-07-22 | 1994-11-08 | 2920913 Canada Inc. | Method for sterilizing products with gamma radiation |
US5480658A (en) * | 1993-07-23 | 1996-01-02 | Melman; Steven A. | Ear and skin cleanser |
FR2710529A1 (en) | 1993-09-29 | 1995-04-07 | Zirinis Phedon | Aqueous gel for nasal use, pellets, and process for preparing them |
US5534544A (en) | 1994-08-19 | 1996-07-09 | New England Medical Center Hospitals, Inc. | Surfactants and emulsifying agents to inhibit Helicobacter |
US5543383A (en) | 1994-12-30 | 1996-08-06 | Hampshire Chemical Corp. | Herbicidal compositions comprising solutions of glyphosate and polyurea and/or polyurethane |
US6086921A (en) * | 1995-04-25 | 2000-07-11 | Wintrop-University Hospital | Metal/thiol biocides |
US5817303A (en) | 1995-05-05 | 1998-10-06 | Protein Polymer Technologies, Inc. | Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer |
CZ293968B6 (en) * | 1995-08-29 | 2004-08-18 | Fidiaáadvancedábiopolymersźásrl | Compound biomaterial for inhibiting surgical adhesions of tissue, use thereof and method |
FI955389A0 (en) * | 1995-11-09 | 1995-11-09 | Antti Sakari Aaltonen | Prophylactic prophylactic preparations and administration of breast cancer pathogens |
US6423694B1 (en) * | 1996-02-21 | 2002-07-23 | Inspire Pharmaceuticals, Inc. | Method of treating otitis media with uridine triphosphates and related compounds |
US6541460B2 (en) * | 1996-08-07 | 2003-04-01 | George D. Petito | Method for use of hyaluronic acid in wound management |
US5910420A (en) * | 1996-08-16 | 1999-06-08 | Orion-Yhtyma Oy Orion Diagnostica | Method and test kit for pretreatment of object surfaces |
US6063061A (en) | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6203822B1 (en) * | 1996-09-03 | 2001-03-20 | University Of Iowa Research Foundation | Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection |
CO4910145A1 (en) | 1996-10-01 | 2000-04-24 | Smithkline Beecham Corp | USE |
AU724070B2 (en) | 1996-10-01 | 2000-09-14 | Smithkline Beecham Corporation | Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms |
IT1287967B1 (en) * | 1996-10-17 | 1998-09-10 | Fidia Spa In Amministrazione S | PHARMACEUTICAL PREPARATIONS FOR LOCAL ANESTHETIC USE |
US5709546A (en) * | 1996-11-27 | 1998-01-20 | Waggoner; Mark B. | Water sanitizing system and process |
FR2756739B1 (en) * | 1996-12-05 | 2000-04-28 | Astra Ab | NEW BUDESONIDE FORMULATION |
PT975790E (en) * | 1997-01-24 | 2005-01-31 | Schweiz Serum & Impfinst | NEW METHOD FOR ISOLATING POLYSACCHARIDES |
US6869938B1 (en) * | 1997-06-17 | 2005-03-22 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use in reducing adhesions |
US5925334A (en) * | 1997-08-27 | 1999-07-20 | Rubin; Bruce K. | Use of surface active agents to promote mucus clearance |
US6638621B2 (en) * | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
JP4754067B2 (en) * | 1997-12-02 | 2011-08-24 | アルキメデス ディヴェロプメント リミテッド | Composition for nasal administration |
US5895781A (en) * | 1997-12-22 | 1999-04-20 | S. C. Johnson & Son, Inc. | Cleaning compositions for ceramic and porcelain surfaces and related methods |
EP1054679B1 (en) * | 1997-12-24 | 2003-02-12 | Britannia Pharmaceuticals Limited | Use of surface active agent for the manufacture of a medicament for treatment of disorders of the middle ear |
IL123143A (en) * | 1998-02-02 | 2001-08-26 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing mupirocin |
US7691829B2 (en) * | 1998-03-24 | 2010-04-06 | Petito George D | Composition and method for healing tissues |
CN100360651C (en) * | 1998-03-27 | 2008-01-09 | 诺沃奇梅兹有限公司 | Acidic cleaning composition comprising acidic protease |
US6824793B1 (en) * | 1998-06-01 | 2004-11-30 | Chiron Corporation | Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants |
US20030079758A1 (en) * | 1998-06-03 | 2003-05-01 | Siegel Phyllis B. | Process and composition for removing biofilm |
US6706290B1 (en) * | 1998-07-06 | 2004-03-16 | Olvai E. Kajander | Methods for eradication of nanobacteria |
US6395746B1 (en) * | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
GB9822170D0 (en) | 1998-10-13 | 1998-12-02 | Danbioyst Uk Ltd | Novel formulations of fexofenadine |
WO2000027438A1 (en) * | 1998-11-06 | 2000-05-18 | Universite De Montreal | Improved bactericidal and non-bactericidal solutions for removing biofilms |
US8197461B1 (en) * | 1998-12-04 | 2012-06-12 | Durect Corporation | Controlled release system for delivering therapeutic agents into the inner ear |
US6375963B1 (en) * | 1999-06-16 | 2002-04-23 | Michael A. Repka | Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof |
US6576224B1 (en) * | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
US6533749B1 (en) * | 1999-09-24 | 2003-03-18 | Medtronic Xomed, Inc. | Angled rotary tissue cutting instrument with flexible inner member |
MXPA02003130A (en) * | 1999-09-24 | 2004-04-21 | Alcon Inc | Topical suspension formulations containing ciprofloxacin and dexamethasone. |
US6156294A (en) * | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
US6676930B2 (en) * | 1999-11-28 | 2004-01-13 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
GB0002229D0 (en) * | 2000-02-01 | 2000-03-22 | Reckitt & Colman Inc | Improvements in or relating to organic compositions |
ES2220733T3 (en) * | 2000-02-28 | 2004-12-16 | THE PROCTER & GAMBLE COMPANY | ANTIMICROBIAL COMPOSITIONS ACID TO TREAT FOODS AND SURFACES OF CONTACT WITH FOODS AND THEIR METHODS OF USE. |
CA2410796C (en) * | 2000-06-05 | 2007-05-01 | S.C. Johnson & Son, Inc. | Biocidal cleaning method |
US6953772B2 (en) * | 2000-07-18 | 2005-10-11 | Lopes John A | Concentrated sanitizing compositions for cleaning food and food contact surfaces |
AUPQ893200A0 (en) * | 2000-07-21 | 2000-08-17 | Whiteley, Reginald K. | Medical residue treatment |
US20030133883A1 (en) * | 2001-06-14 | 2003-07-17 | Finnegan Mary Beth | Oral care compositions containing grapefruit seed extract |
WO2002089750A2 (en) * | 2001-01-19 | 2002-11-14 | Advanced Photodynamic Technologies, Inc. | Apparatus and method of photodynamic eradication of organisms utilizing pyrrolnitrin |
US6610314B2 (en) * | 2001-03-12 | 2003-08-26 | Kimberly-Clark Worldwide, Inc. | Antimicrobial formulations |
AU2002303832A1 (en) | 2001-05-21 | 2002-12-03 | Beth Israel Deaconess Medical Center, Inc. | P.aeruginosa mucoid exopolysaccharide specific binding peptides |
CA2459930C (en) * | 2001-09-21 | 2009-11-10 | Alcon, Inc. | Method of treating middle ear infections |
US20030095890A1 (en) * | 2001-09-24 | 2003-05-22 | Shirley Miekka | Methods for sterilizing biological materials containing non-aqueous solvents |
US20030064000A1 (en) * | 2001-09-24 | 2003-04-03 | Wilson Burgess | Methods of sterilizing biological mixtures using stabilizer mixtures |
AU2003205227A1 (en) | 2002-01-18 | 2003-09-02 | Emory University | Phthalocyanine and porphyrazine pharmaceutical compositions |
US20050042240A1 (en) * | 2002-01-28 | 2005-02-24 | Utterberg David S. | High viscosity antibacterials |
AU2003225073A1 (en) | 2002-04-18 | 2003-11-03 | The University Of Iowa Research Foundation | Methods of inhibiting and treating bacterial biofilms by metal chelators |
US6919348B2 (en) * | 2002-05-02 | 2005-07-19 | Edward T. Wei | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith |
EP1374856A1 (en) | 2002-06-18 | 2004-01-02 | Impetus AG | Oily thixotropic nasal spray |
US7045492B2 (en) * | 2002-07-30 | 2006-05-16 | Earl Jenevein | Cleaning composition comprising cationic surfactants, chelant, and an alcohol solvent mixture |
AU2003272517A1 (en) * | 2002-09-13 | 2004-04-30 | Zicam, Llc. | Compositions to reduce congestion and methods for application thereof to the nasal membrane |
US20050064508A1 (en) * | 2003-09-22 | 2005-03-24 | Semzyme | Peptide mediated synthesis of metallic and magnetic materials |
WO2004026267A2 (en) * | 2002-09-23 | 2004-04-01 | Genta Inc. | Tri(alkylcarboxylato) gallium (iii) products and pharmaceutical compositions containing them |
US20040101506A1 (en) * | 2002-11-25 | 2004-05-27 | Fust Charles A. | Composition for the prevention and treatment of inflammation of the ear |
US7220431B2 (en) * | 2002-11-27 | 2007-05-22 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
GB2397067B (en) * | 2002-12-23 | 2005-05-11 | Destiny Pharma Ltd | Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation |
US7544192B2 (en) * | 2003-03-14 | 2009-06-09 | Sinexus, Inc. | Sinus delivery of sustained release therapeutics |
US20040214753A1 (en) * | 2003-03-20 | 2004-10-28 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
US7090882B2 (en) * | 2003-06-12 | 2006-08-15 | Cargill, Incorporated | Antimicrobial salt solutions for food safety applications |
US20050003007A1 (en) * | 2003-07-02 | 2005-01-06 | Michele Boix | Method of sterilization of polymeric microparticles |
US7341983B2 (en) * | 2003-08-04 | 2008-03-11 | Ecolab Inc. | Antimicrobial compositions including carboxylic acids and alkoxylated amines |
MXPA06001776A (en) * | 2003-08-15 | 2007-09-07 | Qlt Usa Inc | Adhesive bioerodible transmucosal drug delivery system. |
US20050080396A1 (en) * | 2003-10-03 | 2005-04-14 | Michael Rontal | Method and apparatus for the ultrasonic cleaning of biofilm coated surfaces |
NZ547884A (en) * | 2003-12-04 | 2009-10-30 | Univ Iowa Res Found | Gallium inhibits biofilm formation |
ZA200605583B (en) * | 2003-12-17 | 2009-06-24 | Titan Pharmaceuticals Inc | Use of gallium to treat inflammatory arthritis |
EP2286791B1 (en) * | 2003-12-30 | 2014-03-26 | Durect Corporation | Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents |
EP1729676A1 (en) * | 2004-03-15 | 2006-12-13 | Durect Corporation | Pharmaceutical compositions for administration to a sinus |
CA2561496A1 (en) * | 2004-04-02 | 2005-10-20 | Baylor College Of Medicine | Novel modification of medical prostheses |
US7410480B2 (en) * | 2004-04-21 | 2008-08-12 | Acclarent, Inc. | Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders |
US7803150B2 (en) * | 2004-04-21 | 2010-09-28 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
US20050282722A1 (en) | 2004-06-16 | 2005-12-22 | Mcreynolds Kent B | Two part cleaning composition |
US7494963B2 (en) * | 2004-08-11 | 2009-02-24 | Delaval Holding Ab | Non-chlorinated concentrated all-in-one acid detergent and method for using the same |
US20060045850A1 (en) * | 2004-08-30 | 2006-03-02 | Qpharma, Llc | Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids |
US9028852B2 (en) * | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
US20080248558A1 (en) * | 2004-09-10 | 2008-10-09 | Novozymes A/S | Methods For Preventing, Removing, Reducing, or Disrupting Biofilm |
EP1858506A2 (en) * | 2005-03-10 | 2007-11-28 | 3M Innovative Properties Company | Methods of treating ear infections |
WO2006099386A2 (en) * | 2005-03-11 | 2006-09-21 | Massachusetts Institute Of Technology | Synthesis and use of colloidal iii-v nanoparticles |
US8486472B2 (en) * | 2006-01-18 | 2013-07-16 | Cargill, Incorporated | Antimicrobial salt solutions for food safety applications |
US7993675B2 (en) * | 2006-05-10 | 2011-08-09 | Medtronic Xomed, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
US20070264296A1 (en) | 2006-05-10 | 2007-11-15 | Myntti Matthew F | Biofilm extracellular polysachharide solvating system |
US7976873B2 (en) * | 2006-05-10 | 2011-07-12 | Medtronic Xomed, Inc. | Extracellular polysaccharide solvating system for treatment of bacterial ear conditions |
US7959943B2 (en) * | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
JP5151429B2 (en) | 2007-12-05 | 2013-02-27 | 住友化学株式会社 | Aqueous suspension pesticide composition |
EP2303254B1 (en) | 2008-06-12 | 2019-10-30 | Medtronic Xomed, Inc. | Product for treating chronic wounds with an extracellular polymeric substance solvating system |
US20100086576A1 (en) | 2008-10-06 | 2010-04-08 | Myntti Matthew F | Antimicrobial composition and methods of making and using same |
CA2835211C (en) | 2011-05-10 | 2019-09-24 | Next Science, Llc | Antimicrobial solid and methods of making and using same |
-
2009
- 2009-10-05 US US12/573,340 patent/US20100086576A1/en not_active Abandoned
- 2009-10-05 WO PCT/US2009/059504 patent/WO2010042427A2/en active Application Filing
- 2009-10-05 EP EP09819706A patent/EP2346324A4/en not_active Ceased
-
2012
- 2012-11-16 US US13/679,994 patent/US8940792B2/en active Active
-
2013
- 2013-03-20 US US13/847,876 patent/US20130272922A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6149822A (en) * | 1999-03-01 | 2000-11-21 | Polymer Ventures, Inc. | Bio-film control |
US6701940B2 (en) * | 2001-10-11 | 2004-03-09 | S. C. Johnson & Son, Inc. | Hard surface cleaners containing ethylene oxide/propylene oxide block copolymer surfactants |
US20080274932A1 (en) * | 2007-05-04 | 2008-11-06 | Ecolab Inc. | Composition for in situ manufacture of insoluble hydroxide when cleaning hard surfaces and for use in automatic warewashing machines and methods for manufacturing and using |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017069820A2 (en) | 2015-07-17 | 2017-04-27 | Next Science, Llc | Antimicrobial composition having efficacy against endospores |
WO2017069820A3 (en) * | 2015-07-17 | 2017-05-26 | Next Science, Llc | Antimicrobial composition having efficacy against endospores |
CN107920532A (en) * | 2015-07-17 | 2018-04-17 | 贴近科学Ip控股私人有限公司 | Antimicrobial compositions with anti-endospore effect |
US20190014777A1 (en) * | 2015-07-17 | 2019-01-17 | Next Science IP Holdings Pty Ltd | Antimicrobial composition having efficacy against endospores |
EP3337325A4 (en) * | 2015-07-17 | 2019-02-13 | Next Science IP Holdings Pty Ltd | Antimicrobial composition having efficacy against endospores |
US10827750B2 (en) * | 2015-07-17 | 2020-11-10 | Next Science IP Holdings Pty Ltd | Antimicrobial composition having efficacy against endospores |
US20210176987A1 (en) * | 2015-07-17 | 2021-06-17 | Next Science IP Holdings Pty Ltd | Antimicrobial composition having efficacy against endospores |
EP4011210A1 (en) | 2015-07-17 | 2022-06-15 | Next Science IP Holdings Pty Ltd | Use of an antimicrobial composition having efficacy against endospores |
US11723361B2 (en) * | 2015-07-17 | 2023-08-15 | Next Science IP Holdings Pty Ltd | Antimicrobial composition having efficacy against endospores |
WO2022147055A1 (en) * | 2020-12-29 | 2022-07-07 | Next Science IP Holdings Pty Ltd | Cancer treatment composition and method |
Also Published As
Publication number | Publication date |
---|---|
US20130079407A1 (en) | 2013-03-28 |
WO2010042427A2 (en) | 2010-04-15 |
EP2346324A2 (en) | 2011-07-27 |
WO2010042427A3 (en) | 2010-07-01 |
US8940792B2 (en) | 2015-01-27 |
US20100086576A1 (en) | 2010-04-08 |
EP2346324A4 (en) | 2012-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8940792B2 (en) | Antimicrobial composition and methods for using same | |
US20220125045A1 (en) | High Osmolarity Antimicrobial Composition Containing One or More Organic Solvents | |
JP6785789B2 (en) | Antimicrobial composition | |
CN109561694B (en) | Antimicrobial compositions | |
JP7058490B2 (en) | Antibacterial composition that suppresses viruses, bacteria and fungi | |
US20070286907A1 (en) | Germicide composition | |
JPH07252105A (en) | Liquid disinfectant | |
US20140314738A1 (en) | Disinfecting composition | |
WO2014060755A1 (en) | Cleaning, sanitizing and sterilizing preparations | |
CZ36799U1 (en) | Disinfectant | |
CN1565196A (en) | Safe and environment-friendly type surface disinfector | |
US20210176995A1 (en) | Disinfection Composition Comprising Tartaric Acid and Lactic Acid | |
WO2022079626A1 (en) | Antimicrobial composition, particularly bactericidal, virucidal, fungicidal and mycobacterial for the cleaning of contaminated surfaces and its use | |
PL244085B1 (en) | Disinfectant with long-term effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MICROBIAL DEFENSE SYSTEMS LLC, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MYNTTI, MATTHEW F., DR.;REEL/FRAME:030725/0340 Effective date: 20120317 Owner name: NEXT SCIENCE, LLC, FLORIDA Free format text: CHANGE OF NAME;ASSIGNOR:MICROBIAL DEFENSE SYSTEMS LLC;REEL/FRAME:030715/0702 Effective date: 20130501 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |
|
AS | Assignment |
Owner name: NEXT SCIENCE IP HOLDINGS PTY LTD, AUSTRALIA Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:NEXT SCIENCE, LLC;REEL/FRAME:045344/0297 Effective date: 20180116 |